| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/092986711798194388 |
| P953 | full work available online at | http://eurekaselect.com/article/download/75667 |
| https://europepmc.org/articles/PMC3330700 | ||
| https://europepmc.org/articles/pmc3330700?pdf=render | ||
| https://europepmc.org/articles/PMC3330700?pdf=render | ||
| P932 | PMC publication ID | 3330700 |
| P698 | PubMed publication ID | 22087839 |
| P5875 | ResearchGate publication ID | 51802480 |
| P2093 | author name string | J. Yan | |
| D. Tang | |||
| F. Wei | |||
| P2860 | cites work | PML regulates p53 stability by sequestering Mdm2 to the nucleolus | Q24296743 |
| ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex | Q24298863 | ||
| A family of human cdc2-related protein kinases | Q24300226 | ||
| ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation | Q24523440 | ||
| An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. | Q42922881 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 | ||
| KSR1 is required for cell cycle reinitiation following DNA damage | Q43167066 | ||
| Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens | Q45158689 | ||
| The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 with ATR. | Q45936344 | ||
| Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. | Q45957588 | ||
| How cells activate ATR. | Q46064987 | ||
| Trial offers early test case for personalized medicine | Q46142428 | ||
| Delocalization of nucleolar poly(ADP-ribose) polymerase-1 to the nucleoplasm and its novel link to cellular sensitivity to DNA damage | Q46162716 | ||
| ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses | Q53500362 | ||
| A Rad3–Rad26 complex responds to DNA damage independently of other checkpoint proteins | Q63383723 | ||
| MEK/MAPK inhibitors | Q82575726 | ||
| DNA Damage–Induced Modulation of GLUT3 Expression Is Mediated through p53-Independent Extracellular Signal-Regulated Kinase Signaling in HeLa Cells | Q39651536 | ||
| ERK1 and ERK2 kinases activate hydroxyurea-induced S-phase checkpoint in MCF7 cells by mediating ATR activation | Q39655976 | ||
| Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation | Q39679180 | ||
| KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach | Q39720116 | ||
| A comparison of BRCA1 nuclear localization with 14 DNA damage response proteins and domains: identification of specific differences between BRCA1 and 53BP1 at DNA damage-induced foci | Q39797524 | ||
| Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage | Q39812237 | ||
| Coactivation of ATM/ERK/NF-kappaB in the low-dose radiation-induced radioadaptive response in human skin keratinocytes. | Q39867836 | ||
| The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. | Q40118652 | ||
| Irradiation-induced G2/M checkpoint response requires ERK1/2 activation | Q40171624 | ||
| Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response | Q40174240 | ||
| Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death | Q40206033 | ||
| DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. | Q40355325 | ||
| BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. | Q40453486 | ||
| ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. | Q40753388 | ||
| Requirement for ERK activation in cisplatin-induced apoptosis | Q40854460 | ||
| Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin | Q40859019 | ||
| Unwind and slow down: checkpoint activation by helicase and polymerase uncoupling | Q41888313 | ||
| How ATR turns on: TopBP1 goes on ATRIP with ATR. | Q42535886 | ||
| ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function | Q42809820 | ||
| Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions | Q24532168 | ||
| Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro | Q24550745 | ||
| Replication protein A-mediated recruitment and activation of Rad17 complexes | Q24631467 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| Emerging common themes in regulation of PIKKs and PI3Ks | Q24647293 | ||
| Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs | Q24647635 | ||
| Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes | Q27860662 | ||
| CDK inhibitors: positive and negative regulators of G1-phase progression | Q27860983 | ||
| The DNA Damage Response: Making It Safe to Play with Knives | Q27861055 | ||
| The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast | Q27934134 | ||
| LCD1: an essential gene involved in checkpoint control and regulation of the MEC1 signalling pathway in Saccharomyces cerevisiae | Q27938784 | ||
| The DNA damage response: putting checkpoints in perspective | Q28131713 | ||
| An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication | Q28204037 | ||
| DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation | Q28206029 | ||
| ATR and ATRIP: Partners in Checkpoint Signaling | Q28207471 | ||
| Mitotic and G 2 Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216 | Q28247771 | ||
| Cellular dynamics and modulation of WRN protein is DNA damage specific | Q28266300 | ||
| Guilty as charged: B-RAF is a human oncogene | Q28288202 | ||
| The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition | Q28301955 | ||
| Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells | Q28306394 | ||
| ATR: an essential regulator of genome integrity | Q29547883 | ||
| TopBP1 activates the ATR-ATRIP complex | Q29614214 | ||
| Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage | Q29614218 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells | Q29618480 | ||
| Coordinating ERK/MAPK signalling through scaffolds and inhibitors | Q29618995 | ||
| The mitogen-activated protein kinase signal transduction pathway | Q29620226 | ||
| Function of a conserved checkpoint recruitment domain in ATRIP proteins | Q33276978 | ||
| BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines | Q33523959 | ||
| In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase | Q33557673 | ||
| Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites | Q33589782 | ||
| ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks | Q33802003 | ||
| Contributions made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progenitor cells | Q33808811 | ||
| Requirement of MTA1 in ATR-mediated DNA damage checkpoint function | Q33924254 | ||
| Docking domains and substrate-specificity determination for MAP kinases | Q34023280 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex | Q34311086 | ||
| Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models | Q34427548 | ||
| The Raf/MEK/ERK pathway: new concepts of activation. | Q34454912 | ||
| Activation and regulation of ATM kinase activity in response to DNA double-strand breaks | Q34722727 | ||
| Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer | Q34773458 | ||
| DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes | Q34967711 | ||
| An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila. | Q34985294 | ||
| Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. | Q35006842 | ||
| Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase | Q35186927 | ||
| MAPK pathways in radiation responses | Q35208830 | ||
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 | ||
| Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex | Q35848485 | ||
| Chk1 in the DNA damage response: conserved roles from yeasts to mammals | Q35848488 | ||
| Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis | Q35848561 | ||
| A novel mutant allele of Schizosaccharomyces pombe rad26 defective in monitoring S-phase progression to prevent premature mitosis | Q36568579 | ||
| TopBP1 activates ATR through ATRIP and a PIKK regulatory domain | Q36706894 | ||
| Protein trafficking in response to DNA damage | Q36773129 | ||
| Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells | Q36868759 | ||
| Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. | Q36881759 | ||
| ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes | Q37038890 | ||
| Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. | Q37222088 | ||
| The Werner syndrome protein functions in repair of Cr(VI)-induced replication-associated DNA damage | Q37256608 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| Galectin-3 protects keratinocytes from UVB-induced apoptosis by enhancing AKT activation and suppressing ERK activation | Q37401349 | ||
| Ras signaling and therapies | Q37548931 | ||
| The S-phase checkpoint: targeting the replication fork | Q37580933 | ||
| Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors | Q37798827 | ||
| New druggable targets in the Ras pathway? | Q37820535 | ||
| Mutant BRAF Melanomas—Dependence and Resistance | Q37830845 | ||
| Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Q37866945 | ||
| Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. | Q37892769 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| Pie1, a protein interacting with Mec1, controls cell growth and checkpoint responses in Saccharomyces cerevisiae | Q39457690 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | extracellular signal-regulated kinases | Q409325 |
| neoplasm | Q1216998 | ||
| DNA damage | Q5205747 | ||
| protein kinase inhibitors | Q7251487 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 5476-5482 | |
| P577 | publication date | 2011-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Medicinal Chemistry | Q3007710 |
| P1476 | title | Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy | |
| Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy | |||
| P478 | volume | 18 |
| Q38733038 | Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor. |
| Q93053122 | Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS-Mediated Downregulation of Flap Endonuclease 1 |
| Q45236427 | BMI1 reduces ATR activation and signalling caused by hydroxyurea |
| Q64951143 | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. |
| Q24297805 | Collaborator of ARF (CARF) regulates proliferative fate of human cells by dose-dependent regulation of DNA damage signaling |
| Q35745893 | Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. |
| Q38715267 | Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway |
| Q54982256 | Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis. |
| Q36680834 | DNA Damage Response Is Involved in the Developmental Toxicity of Mebendazole in Zebrafish Retina. |
| Q46796266 | Effect of silver nanoparticles on mitogen-activated protein kinases activation: role of reactive oxygen species and implication in DNA damage |
| Q42199612 | Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency |
| Q40982017 | Gallium Nanoparticle-Mediated Reduction of Brain Specific Serine Protease-4 in an Experimental Metastatic Cancer Model |
| Q41612485 | Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity |
| Q39039916 | Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. |
| Q33624594 | Microvesicles Contribute to the Bystander Effect of DNA Damage |
| Q46433369 | N-acetyl-L-cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells |
| Q37605218 | Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma |
| Q47742525 | Potential hazards of fenvalerate in massive pollution influence the apoptosis sensitivity |
| Q28396412 | ROS/Autophagy/Nrf2 Pathway Mediated Low-Dose Radiation Induced Radio-Resistance in Human Lung Adenocarcinoma A549 Cell |
| Q44670997 | Screening Novel Molecular Targets of Metformin in Breast Cancer by Proteomic Approach |
| Q64990834 | The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. |
| Q38832228 | The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway. |
| Q35743835 | Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF-κB pathways and their target, IEX-1 |
| Q33865519 | Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling |
| Q35832914 | XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression |
| Q64389647 | cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage |
Search more.